'Treatment of chronically infected mice with either αPD-1 or αPD-L1 antibody not only increased effector cell differentiation from the virus-specific stem-like CD8 T cells but also increased their proliferation so their numbers were maintained'

#Immunology #Immunotherapy

https://www.science.org/doi/10.1126/sciimmunol.adg0539

"Although marketed CAR-T therapies have shown transformative efficacy for certain blood cancers, widespread adoption, as well as applicability to solid tumours and autoimmune indications, have been limited by safety, efficacy and operational hurdles. These hurdles include high rates of adverse events such as cytokine release syndrome (CRS), inability to overcome the immunosuppressive microenvironment typically found in solid tumours, and antigen escape and cell exhaustion that reduce durability."

#CARTCells #Immunotherapy #Immunology

https://www.nature.com/articles/d41573-023-00140-7

'Our study revealed that, in cancer immunotherapy, there is a strong correlation between clinical outcome and 1-year milestone survival rate, but weak associations with other intermediate endpoints including ORR, disease control rate, and PFS.'
#Immunology #Immunotherapy #immuneoncology

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00333-4/fulltext

"In this review we analyze memory T cell subtypes based on their potential utility in cancer immunoprevention with regard to longevity, localization, activation requirements, and efficacy in fighting cancers."
#Immunology #Immunotherapy

https://journals.aai.org/jimmunol/article-abstract/211/6/907/265865/Memory-T-Cells-in-the-Immunoprevention-of-Cancer-A?redirectedFrom=fulltext

"Another key parameter in CAR T cell infusion products is the ratio of CD4:CD8 T cell subsets. Yet, it is unclear whether CD4+ and CD8+ CAR T cells have the same propensity to induce CRS. This is particularly relevant since CD4:CD8 ratios can vary extensively in distinct infusion products."

#Immunology #immunotherapy #CARTCells

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00314-2

The preclinical work on CD47, which binds SIRPα to deliver a 'don't eat me signal', was very compelling. But as a druggable target it's had a bumpy ride in clinical development.

'Pfizer executives were bullish during a second quarter earnings call Thursday that its two CD47 meds would not face the same setbacks seen from rivals Gilead and others. As a result, the New York pharma is staying the course.'
(HT Michael Tomasson)
#Immunology #immunotherapy #InnateImmunity

https://www.fiercebiotech.com/biotech/pfizer-undeterred-cd47-plans-competitors-face-pitfalls

Personalized RNA #vaccines for #melanoma advance to phase III trials (in combination with anti-PD1).
My latest Clinical Pipeline column for @NatureMedicine #Immunology #Immunotherapy
https://www.nature.com/articles/d41591-023-00072-0

First in human trials of a CART cell using a llama single domain ab construct targeting mesothelin in solid tumors.

#Immunology #Immunotherapy

https://www.nature.com/articles/s41591-023-02452-y

'We used the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional antigen-presenting cells (tumor-APCs). Enforced expression of the transcription factors PU.1, IRF8, and BATF3 (PIB) was sufficient to induce the cDC1 phenotype in 36 cell lines derived from human and mouse hematological and solid tumors.'

#Immunology #Immunotherapy

https://www.science.org/doi/10.1126/sciimmunol.add4817

Ars Technica: T cells burn out just a few hours after encountering cancer tumors https://arstechnica.com/?p=1959111 #Tech #arstechnica #IT #Technology #immuneresponse #immunotherapy #Science #t-ceels #Health #cancer #tcells

BCMA targeting CARTs in #MultipleMyeloma

"At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group."

#Immunology #immunotherapy #cartcells

https://www.nejm.org/doi/full/10.1056/NEJMoa2303379?query=featured_home

Postdoc in Biochemistry, Cell and Molecular Biology

UT Southwestern

See the full job description on jobRxiv: https://jobrxiv.org/job/ut-southwestern-27778-postdoc-in-biochemistry-cell-and-molecular-biology-4/?feed_id=51823

#ScienceJobs #hiring #research #postdoc #metabolism #biochemistry #molecularbiology #immunotherapy #infection #immunity #cancer
Dallas #UnitedStatesUS #P...
https://jobrxiv.org/job/ut-southwestern-27778-postdoc-in-biochemistry-cell-and-molecular-biology-4/?feed_id=51823

Postdoc in Biochemistry, Cell and Molecular Biology

UT Southwestern

See the full job description on jobRxiv: https://jobrxiv.org/job/ut-southwestern-27778-postdoc-in-biochemistry-cell-and-molecular-biology-4/?feed_id=50771

#ScienceJobs #hiring #research #postdoc #metabolism #biochemistry #molecularbiology #immunotherapy #infection #immunity #cancer
Dallas #UnitedStatesUS #P...
https://jobrxiv.org/job/ut-southwestern-27778-postdoc-in-biochemistry-cell-and-molecular-biology-4/?feed_id=50771

Could fecal transplants provide relief
For suffering from melanoma grief?
Phase 1 said yes
It's safe, no fewer dis
The results could offer a reprieve

#fecaltransplant #melanoma #immunotherapy #clinicaltrial #limerick #poetry

http://www.medicalnewstoday.com/articles/could-fecal-transplants-improve-melanoma-treatment

Researchers in @ScienceAdvances have identified specific pancreatic #cancer traits that allow cells to evade treatment. #CRISPR screens reveal multiple targets to improve #immunotherapy for better patient outcomes. https://scim.ag/3oB #press

Biomaterial-delivered one-two punch boosts cancer immunotherapy #cancer #immunotherapy https://wyss.harvard.edu/news/biomaterial-delivered-one-two-punch-boosts-cancer-immunotherapy/

'In this Review, we present current knowledge on the role of MDSCs in the immunotherapy of melanoma. We describe the accumulation, infiltration, and immunosuppressive functions of MDSCs in the tumor microenvironment (TME) as well as existing therapeutic strategies to target them in melanoma-bearing hosts. A special focus is placed on preclinical studies and clinical trials applying MDSC inhibition to overcome resistance to ICIs.'

#immunology #immunotherapy #immunooncology

https://www.jci.org/articles/view/170762

Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial #oncolytic #immunotherapy #intratumoral #CRC #cancer

https://jitc.bmj.com/content/11/5/e006774

'I had repeatedly heard, “Immunology will never be a therapy for cancer patients.” Then Jim Allison started presenting patients who were responding to anti–CTLA-4, and all of a sudden, we went from night to day.'
- Elizabeth Jaffee

#Immunology #immunotherapy

https://www.jci.org/articles/view/172246

'Here, we show in multiple cancer models that CXCR3+ Treg cells were increased in tumors compared with lymphoid tissues, exhibited an activated phenotype, and interacted preferentially with CXCL9-producing BATF3+ dendritic cells (DCs). Genetic ablation of CXCR3 in Treg cells disrupted DC1-Treg cell interactions and concomitantly increased DC-CD8+ T cell interactions.'

#Immunology #TumorImmunology #immunotherapy

https://www.cell.com/immunity/fulltext/S1074-7613(23)00260-1